Ratings Intco Medical Technology Co., Ltd.

Equities

300677

CNE100003456

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 25/04/2024 BST			5-day change	1st Jan Change
26.14 ^CNY	+5.45%		+16.13%	+11.90%

04-25	Intco Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-24	Intco Medical Technology Co., Ltd. Proposes Final Dividend for 2023	CI

Summary

The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
INTCO MEDICAL TECHNOLOGY CO., LTD.	+11.90%	2.34B	-	A-
COLOPLAST A/S	+11.84%	27.79B		B+
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	-32.98%	2.98B		B-
WINNER MEDICAL CO., LTD.	-15.97%	2.52B		C+
HARTALEGA HOLDINGS	-1.11%	1.91B		B
HARBIN FUERJIA TECHNOLOGY CO., LTD.	-13.37%	1.83B		-
TOP GLOVE CORPORATION BHD.	-7.78%	1.39B		B
NAKANISHI INC.	-0.38%	1.27B		-
KANGJI MEDICAL HOLDINGS LIMITED	+4.01%	1.13B		-
KOSSAN RUBBER INDUSTRIES	+13.51%	1.12B		C

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes